Acelot has dosed the first healthy volunteer in a Phase 1a clinical trial testing ACE-2223, its investigational oral treatment candidate designed to target aggregated TDP-43 in people with amyotrophic lateral sclerosis (ALS). In the vast majority of people with ALS, the TDP-43 protein moves to the wrong place in…
News
Geneuro has received a European patent for GNK-301, its experimental therapy designed to target a viral protein thought to contribute to amyotrophic lateral sclerosis (ALS), and plans to begin Phase 1 clinical trials in the second half of 2027. The antibody-based therapy was developed through a partnership between…
Paradromics’ investigational Connexus brain-computer interface (BCI) enabled a woman with a progressive motor neuron disease to generate her own words in real time, answer open-ended questions, and communicate with her family using synthesized speech. The woman, who had a severe impairment of her ability to speak, was the first…
Mindy Henderson has spent much of her life challenging the limits others have placed on her. When she was diagnosed with spinal muscular atrophy (SMA) — a genetic condition that causes muscles to weaken over time — as an infant, doctors told her parents that she might not live long…
Coya Therapeutics is approaching full enrollment in its main clinical trial for COYA 302, an experimental therapy for amyotrophic lateral sclerosis (ALS), having signed on its 100th participant. The Phase 2/3 ALSTARS trial (NCT07161999) aims to recruit 120 adults with ALS across sites in the U.S.
Five Canadian students personally affected by amyotrophic lateral sclerosis (ALS) will each receive $2,500 to support their studies in the 2026-2027 academic year. The ALS Canada Kevin Daly Bursary award winners were chosen for their contributions to the ALS community through caregiving, advocacy, fundraising, volunteering, or awareness efforts. The bursary…
Filmmaker and University of Virginia graduate Chris Farina had the idea for a documentary about death and dying about 10 years ago. Now he’s in the final stages of amyotrophic lateral sclerosis (ALS), and is relying on friends to help him complete the project. One of those friends is…
Among people living with amyotrophic lateral sclerosis (ALS), requests to be referred for medical assistance in dying, known as MAiD, may have more to do with individual preferences about life-sustaining interventions than disease severity. That’s according to a new Canadian study showing that people with ALS using noninvasive…
Enrollment of adults with mild-to-moderate amyotrophic lateral sclerosis (ALS) has been completed in a clinical trial testing PHENOGENE-1A as an add-on treatment for the neurodegenerative disease. Enrollment of about 105 participants in the Phase 2b trial (NCT07142291) wrapped up in late August, and they were randomly assigned to…
Nearly 500 people gathered in Orlando, Florida, and more than 1,900 joined them online to discuss advances in amyotrophic lateral sclerosis (ALS) research and care and community goals for the future at the third annual ALS Nexus Conference. Clinicians, researchers, patients, caregivers, advocates, industry partners, and others in the…
Recent Posts
- Experimental treatment may help preserve body weight in ALS, data show
- ALS doesn’t have a cure, but compassion helps
- Free online platform launches to support people living with ALS
- Alzheimer’s biomarkers may improve ALS diagnosis, predict outcomes
- MDA Engage: ALS neurologist sees real reasons for renewed optimism